Skip to main content

Table 2 Brentuximab vedotin-based salvage regimens assessed in patients with R/R HL

From: Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Regimen(s) Patients Response before transplant OS PFS
B + DHAP [48] R/R HL (N = 61) • Metabolic CR 79%
• Metabolic PR 8%
• Progressive disease 7%
• 87% of pts. were mobilized and received ASCT
2-year
OS 92%
2-year PFS 76%
BrESHAP [49] R/R HL after frontline chemotherapy (N = 66) • ORR 91%
• CR 82%
• PR 10%
• 64 pts. were mobilized and 60 received SCT
30-month
OS 91%
30-month PFS 71%
PET-adapted brentuximab vedotin + aICE [16] R/R HL who had failed one previous doxorubicin regimen (N = 46) • ~ 30% of pts. achieved PET-negativity with brentuximab vedotin alone
• aICE increased PET-negativity rates to ~ 80%
NR 2-year EFS = 82%
PET-adapted brentuximab vedotin + aICE [50, 51] First relapse or primary refractory CD30+ cHL
(N = 24 [50])
(N = 42 [51])
• 87% CR per investigator, 70% per independent review [50]
• 69.2% CMR [51]
NR 1-year PFS estimate 69% (95% CI 53–81%)
Brentuximab vedotin [52] R/R HL (N = 37) • Best ORR = 69% (CR = 33%)
• 12 pts. with CR received SCT
• 11/13 pts. with PR and all pts. with SD/PR required additional chemotherapy
NR NR
Brentuximab vedotin + bendamustine [53] R/R HL (N = 55) • ORR 92.5%
• CR 73.6%
• 41 patients were mobilized and 40 underwent ASCT
NR 2-year PFS 62.6%
Brentuximab vedotin + nivolumab [54] R/R HL (N = 61) • ORR 82%
• CR 61%
• 54 pts. underwent ASCT
NR 6-month estimated PFS 89%
\